Quantitative Fecal Lactoferrinas a Biomarker for Severe Clostridium difficile Infection in Hospitalized Patients
Journal Title: Journal of Geriatrics and Palliative Care - Year 2014, Vol 2, Issue 1
Abstract
Background: The incidence and severity of Clostridium difficile infection (CDI) have increased over the past decade, especially among hospitalized patients. In this study, we determined the value of published criteria for severe CDI in predicting 3 month mortality, as well as the utility of fecal lactoferrin as a biomarker for severe CDI. Methods: Pilot Year 1 of IRB approved (HSR-IRB# 13630) prospective cohort study of hospitalized patients with CDI at US academic medical center (10/08-4/10). Medical records of hospitalized patients with clinically diagnosed CDI, via toxin assay, were evaluated to objectively define severe CDI based on current guidelines. A stool sample from CDI diagnosis was analyzed for amount of fecal lactoferrin (IBD-SCAN, TechLab, Inc.). Data was analyzed using SPSS for student’s t-test and chi-squared, significance p ≤ 0.05. Results: 79 subjects consented and enrolled, mean age was 64 years (standard deviation, sd, 17.2), 48 (61%) female, and average Charlson co-morbidity score was 5.8 (sd 3.8). Subjects with severe CDI were 5 times more likely to die within 3 months of diagnosis (Odds Ratio 5.66 (95% Confidence Interval 2.03-15.79), p=0.001) and had significantly more fecal lactoferrin (580.0 (sd 989.0) vs. 181.7 (sd 244.2) μg/mL, p=0.018), compared to those that did not meet severe CDI criteria. Conclusion:In this pilot study, subjects who meet defined criteria for severe CDI had higher mortality and more intestinal inflammation. These preliminary results were, however, underpowered to show a direct association of lactoferrin with mortality. Larger cohort studies are needed to optimize a criterion for severe CDI and evaluate a direct association of lactoferrin and mortality in hospitalized patients with CDI.
Authors and Affiliations
Laurie Archbald-Pannone
Keywords
Related Articles
- EP ID EP203937
- DOI 10.13188/2373-1133.1000006
- Views 101
- Downloads 0
What Do The Junior Doctors Know About Pain Management And Opioids Use? : An Australian Study
Background: Pain continues to remain an issue in the general population even though studies have demonstrated that adequate pain management is possible with the use of opioids. This could be related to unwarranted opioph...
Specialty Trainees’ Understanding of End-of-Life Care Symptom Management and End-of-Life Care Pathway: A Quantitative and Qualitative Pilot Study
Introduction: Lack of knowledge of end-of-life care pathway (EOLCP) and misconceptions about opioid use are detrimental toproviding quality care to patients with life-limiting diseases. This study aims to use the mixed-m...
Comparison of Unmet Care Needs across The Dementia Trajectory: Findings from The Maximizing Independence at Home Study
Introduction: The aging of the population will bring with it an increase in the number of individuals with dementia living in the community. This will result in a greater demand on family caregivers and the long term car...
Behavioral and Psychological Symptoms and Caregiver Burden in Mexican Alzheimer’s Disease Patients
Background: Alzheimer’s disease accounts for 60-70% of dementias. An estimated 44 million people worldwide are living with dementia. Caregiver burden is a multidimensional response with physical, emotional, social and fi...
ACEPAC Study - Australian Chinese patient’s Experiences of Palliative Care Services
Background: Australia is a multicultural country that consists of a diverse population. It can be difficult to provide equal healthcare services across all ethnicities due to cultural disparities. This is seen amongst Au...